Katie Gordon
Keine laufenden Positionen mehr
Profil
Prior to joining Harvard's Office of Technology Development in 2004, Dr. Gorgon served as a consultant to several early-stage biomedical companies in the areas of strategic development and operations/management.
She previously founded and ran biotechnology company Apollo BioPharmaceutics, a neuroscience company that developed novel neuroprotective compounds for Alzheimer's disease and ophthalmic indications and was by acquired by MitoKor Corp.
Prior to Apollo/MitoKor, she was a Director at Genzyme Corporation.
Dr. Gordon was a post-doctoral fellow at Yale University and holds a PhD from Wesleyan University.
Ehemalige bekannte Positionen von Katie Gordon
| Unternehmen | Position | Ende |
|---|---|---|
Office of Technology Development
 Office of Technology Development Investment ManagersFinance Office of Technology Development (Office of Technology Development) is a venture capital subsidiary of Harvard University founded in 2007. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | 30.06.2009 |
| LINEAGE CELL THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.04.2006 |
Ausbildung von Katie Gordon
| Wesleyan University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| LINEAGE CELL THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Office of Technology Development
Office of Technology Development Investment ManagersFinance Office of Technology Development (Office of Technology Development) is a venture capital subsidiary of Harvard University founded in 2007. The firm is headquartered in Cambridge, Massachusetts. | Finance |
